Status:
COMPLETED
Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia
Lead Sponsor:
Innovative Medical
Conditions:
Pterygia
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- pts with symptomatic pterygia unresponsive to palliative treatment.
Exclusion
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00383396
Last Update
February 13 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Schechter
Boynton Beach, Florida, United States, 33426